Menu

Federal Science Funding Could Increase Under New Budget Deal

Congress has increased discretionary spending caps, making it possible that the budgets of US science agencies will rise this fiscal year.

Feb 12, 2018
Shawna Williams

ISTOCK, OPENMINDEDEThe budget deal signed into US law on Friday (February 9) increases the caps on nondefense discretionary spending—a category that includes science agencies such as the National Institutes of Health, the National Science Foundation, and NASA—by $143 billion (12.9 percent) in fiscal year 2018, and by $153 billion in 2019, reports the American Association for the Advancement of Science (AAAS). But how those funds will be allocated will not be determined until Congress passes an appropriations bill.

AAAS’s Matt Hourihan tells Science News that “Generally, research and development funding tends to track the discretionary budget pretty closely . . . most likely we're looking at a larger increase this year, and then a far more moderate increase next year. Within that context, agencies will fare better or worse based on their current popularity.”

In response to the news about the deal, which ended a very brief government shutdown, the American Chemical Society (ACS) released a statement that reads in part, “ACS is encouraged by the bipartisan budget deal that includes an increase in domestic spending over two years. ACS encourages Congress to invest heavily in scientific research and education, which are key elements of the U.S. innovation pipeline that drives job creation and economic growth.”

Defense spending caps also increased under Friday’s deal. The White House is expected to release a proposed budget today (February 12) that reflects the new funding limits. Such proposals from the president are not binding, but reflect the administration’s priorities, CNBC reports.

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery introduces Myeloid DNA Reference Standard to support genetic testing of leukemia

Horizon Discovery Group plc, a global leader in gene editing and gene modulation technologies, today announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!